Skip to main content

Table 1 Characteristics of study participation

From: Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus

  SLE OADs Healthy controls p value
(n = 90) (n = 56) (n = 100)
Sex (females/males) 83/7 44/12 87/13 0.058a
Positive IgG ANAs (%) 100% (90/90) 57% (32/56) 3% (3/100) < 0.001a
Positive HA IgG ANA (%) 71% (64/90) 30% (17/56) 0 < 0.001a
  P50 (P25-P75) P50 (P25-P75) P50 (P25-P75)  
Age (years) 34 (27–45) 37(31–46) 33 (28–44) 0.071a
SLEDAI score 14 (10–18) ND ND  
CXCL1 (pg/mL)c 1492.86 (735.47–2887.34) 174.23 (17.07–368.40) 13.58 (8.46–37.22) < 0.001b
An-dsDNA IgG (IU/L)d 1093.37 (448.21–2215.30) 10 (10–10) 10 (10–10) < 0.001b
C3 (g/L)e 0.54 (0.34–0.77) 1.04 (0.86–1.27) 1.09 (0.96–1.23) < 0.001b
C4 (g/L)f 0.09 (0.04–0.12) 0.21 (0.15–0.30) 0.255 (0.21–0.30) < 0.001b
ESR (mm/h)g 25.45 (18.13–54.48) 19.5 (10.7–37.3) 12.75 (7.7–21.43) < 0.001b
CRP (mg/mL)h 1.66 (0.67–5.49) 2.31 (0.92–8.20) 0.44 (0.30–0.57) < 0.001b
Albumin (g/L)i 37.65 (30.88–42.80) 41.3 (35.55–44.53) 45.0 (43.30–46.60) < 0.001b
Neu (×109)j 3.73 (2.60–5.65) 3.29 (2.47–5.03) 3.23 (2.55–4.0) 0.030b
  1. Characteristics of the study populations were shown in Table 1. SLE: Systemic lupus erythematosus; OADs: other autoimmune diseases; HAIgGANA: high-avidity antinuclear antibody (ANA) of the IgG isotype; ND: not detected. SLEDAI: SLE Disease Activity Index; C3/C4: Complement 3/4; ESR: erythrocyte sedimentation ratio; CRP: C-reactive protein; Neu: neutrophils
  2. aData was compared to different groups, the difference was statistically significant. The chi-squared test or Fisher's exact test were used
  3. bData was compared to different groups, the difference was statistically significant. The Kruskal–Wallis H test were used
  4. CSLE versus healthy controls, p < 0.001; SLE versus OAD, p < 0.001; OAD versus healthy controls, p < 0.001
  5. dSLE versus healthy controls, p < 0.001; SLE versus OAD, p < 0.001; OAD versus healthy controls, p = 0.002
  6. eSLE versus healthy controls, p < 0.001; SLE versus OAD, p < 0.001; OAD versus healthy controls, p = 0.011
  7. fSLE versus healthy controls, p < 0.001; SLE versus OAD, p < 0.001; OAD versus healthy controls, p = 0.007
  8. gSLE versus healthy controls, p < 0.001; SLE versus OAD, p = 0.158; OAD versus healthy controls, p < 0.001
  9. hSLE versus healthy controls, p < 0.001; SLE versus OAD, p = 0.094; OAD versus healthy controls, p < 0.001
  10. iSLE versus healthy controls, p < 0.001; SLE versus OAD, p = 0.005; OAD versus healthy controls, p < 0.001
  11. jSLE versus healthy controls, p = 0.007; SLE versus OAD, p = 0.352; OAD versus healthy controls, p = 0.242